Selitrectinib Pediatric
Solid Tumors Harboring NTRK Fusion
BayerPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Solid Tumors Harboring NTRK Fusion cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
bay2757556 Bayer | Phase 2 | BB |
Larotrectinib Bayer | Phase 1/2 | BB |
Selitrectinib Bayer | Phase 1 | CCC |
Entrectinib University of California, San Francisco | Phase 2 | CCC |
Ceritinib University of California, San Francisco | Phase 2 | CCC |
View all 13 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →